Journal: Cell Reports Medicine

Article Title: Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy

doi: 10.1016/j.xcrm.2026.102699

Figure Lengend Snippet: scRNA-seq reveals differential immune infiltration in αOX40-treated tumors based on response (A) Schematic of the bilateral MC38 tumor model assessing αOX40 response. Humanized OX40 mice received three doses of αOX40, followed by resection of the left tumor for scRNA-seq and flow cytometry analysis. Contralateral tumor dynamics and survival were monitored longitudinally. (B) UMAP visualization of scRNA-seq data from immune cells in MC38-bearing mice following αOX40 treatment. Cells are color-coded by annotated cell type. (C) Heatmap depicting nine transcriptionally distinct immune cell subpopulations. (D) Pie chart shows the relative abundance of nine immune cell clusters in αOX40 responders and nonresponders. (E) Flow cytometry analysis of tumor-infiltrating immune cell frequencies in αOX40-treated MC38-bearing mice. Frequencies of CD4 + T cells, CD8 + T cells, and macrophages were quantified after the third αOX40 dose (control, n = 5 mice; mice with a robust therapeutic response named as responder, n = 4 mice; mice with minimal to no response named as nonresponder, n = 4 mice). Data represent mean ± SD from one of two independent experiments (E). Statistical significance was determined using one-way ANOVA with multiple comparisons. ∗∗ p < 0.01.

Article Snippet: The mouse colon cancer MC38 cell line (Cat. NO. NM-S13) and the pancreatic cancer KPC cell line (Cat. NO. NM-YD04) were purchased from Shanghai Model Organisms Center, Inc.

Techniques: Flow Cytometry, Control, Clinical Proteomics

Journal: Cell Reports Medicine

Article Title: Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy

doi: 10.1016/j.xcrm.2026.102699

Figure Lengend Snippet: NOS2-expressing macrophages is associated with response to αOX40 therapy (A) UMAP of monocytes/macrophages subclusters from scRNA-seq data in αOX40-treated MC38-bearing mice. (B) Representative marker genes in the monocyte/macrophage subclusters. (C) Pie chart showing the proportional distribution of monocyte/macrophage subsets of responders and nonresponders. (D) QuSAGE pathway analysis demonstrated enrichment of innate immune and phagocytic signaling pathways in distinct monocyte/macrophage subsets. (E) UMAP showing Mac_C1 signature genes and a heatmap of immune-related gene expression across TAM subclusters ( Z score normalized). (F) Violin plots comparing Nos2 expression levels in Mac_C1 subset between responsive and nonresponsive. (G) Flow cytometry analysis shows the percentage of M1-like (F4/80 + NOS2 + ) and M2-like (F4/80 + CD206 + ) macrophages in tumor tissues of control ( n = 5 mice), nonresponders (with minimal to no response, n = 4 mice), and responders (with a robust therapeutic response, n = 4 mice). (H and I) Comparison of Nos2 expression levels in responders versus nonresponders pre- or post-αOX40 treatment. Bilateral-MC38-bearing mice were treated with αOX40, and tumors from one side were analyzed by RNA-seq prior to (H) or following αOX40 treatment (I). The Nos2 expression was analyzed from RNA-seq data (left) and validated by RT-qPCR (right) ( n = 5 biological replicates). (J) NOS2 expression in tumor biopsies post-treatment determined by RNA-seq. Patients with advanced solid tumors and >1 prior therapy received HFB301001 monotherapy. Tumor biopsy samples were obtained on day 8 of cycle 2 for subsequent RNA-seq analysis. NOS2 expression were compared between patients achieving stable disease (SD, n = 3) and those with progressive disease (PD, n = 3). (K) GO enrichment analysis of upregulated genes in Mac_C1 of responders. (L) Calreticulin expression was quantified by flow cytometry in different response groups following αOX40 treatment ( n = 3 mice per group). (M) NOS2 expression in BMDMs was analyzed by flow cytometry after stimulation with CD8 + T cell supernatant and MC38 lysate, combined with TLR inhibition and IFN-γ blockade ( n = 5 biological replicates). (N) Quantification of Nos2 expression in BMDM by RT-qPCR after 24-h stimulation with MPLA (TLR4 agonist, 100 ng/mL), IFN-γ (20 ng/mL), or both. Data normalized to Gapdh and presented as fold-change relative to unstimulated controls ( n = 4 biological replicates). Data are shown as means ± SD from one of two independent experiments (G, H, I, L, M, and N). Statistical significance was determined using one-way ANOVA with multiple comparisons (G, L, M, and N) or using an unpaired two-tailed t test (H, I, and J). n.s., not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; VST, variance stabilized transformation; sup., supernatant; lys., tumor lysate; inh., inhibitor.

Article Snippet: The mouse colon cancer MC38 cell line (Cat. NO. NM-S13) and the pancreatic cancer KPC cell line (Cat. NO. NM-YD04) were purchased from Shanghai Model Organisms Center, Inc.

Techniques: Expressing, Marker, Protein-Protein interactions, Gene Expression, Flow Cytometry, Control, Clinical Proteomics, Comparison, RNA Sequencing, Quantitative RT-PCR, Inhibition, Two Tailed Test, Transformation Assay

Journal: Cell Reports Medicine

Article Title: Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy

doi: 10.1016/j.xcrm.2026.102699

Figure Lengend Snippet: Rational modulation of tumor microenvironment enhances therapeutic responsiveness to αOX40-based immunotherapy (A–D) OX40-humanized mice bearing subcutaneous MC38 (A), B16 (B), E.G7 (C), or KPC (D) tumors ( n = 5–7 mice per group). Tumor growth curves (numbers indicate complete cures) and Kaplan-Meier survival for each model. Treatments: MPLA+IFN-γ ( i.t. , intratumoral); Combo: MPLA+IFN-γ ( i.t. , intratumoral) + αOX40 ( i.p. , intraperitoneal). (E) Study schema of secondary tumor challenge in MC38 model treated with Combo. (F) Tumor progression and survival outcomes following secondary tumor challenge. Growth kinetics of re-implanted tumors in tumor-cleared mice (previously cured by therapy) versus treatment-naive wild-type controls (left). Kaplan-Meier survival plot (right) ( n = 13 mice per group). (G) Systemic immunity evaluation schema with bilateral MC38 bearing mice were treated with Combo, αOX40, and control. (H) Tumor growth curves and survival plots of (G) ( n = 6–7 mice per group). Data are shown as means ± SD from one of two independent experiments (A–D, F, and H). Statistical significance was determined using log rank test (A–H). n.s., not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The mouse colon cancer MC38 cell line (Cat. NO. NM-S13) and the pancreatic cancer KPC cell line (Cat. NO. NM-YD04) were purchased from Shanghai Model Organisms Center, Inc.

Techniques: Control

Journal: Cell Reports Medicine

Article Title: Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy

doi: 10.1016/j.xcrm.2026.102699

Figure Lengend Snippet: The antitumor efficacy of the Combo therapy is contingent upon CD8 + T cells and macrophages (A) UMAP of scRNA-seq data from tumor-infiltrating immune cells in OX40-humanized MC38-bearing mice treated with MPLA, IFN-γ, αOX40, or Combo. Cells are color-coded by annotated cell type. (B) Bubble chart showing the top variable marker genes for identified immune cell types. (C) Pie chart shows the relative abundance of 11 immune cell clusters in control, αOX40, MPLA+IFN-γ, or Combo. (D) Macrophage frequency and absolute count in tumors of MC38-bearing mice after two and three treatment cycles with MPLA, IFN-γ, αOX40, or Combo, analyzed by flow cytometry ( n = 5 mice per group). (E) Schematic of CD8 + T cell depletion assay. (F) Tumor volume and survival were monitored. Kaplan-Meier survival analysis corresponding to the depletion study of CD8 + T cell ( n = 6 mice per group). (G) Schematic of macrophage depletion assay in early and late stage. (H and I) Tumor volume and survival were monitored. Kaplan-Meier survival analysis corresponding to the depletion study in (G) ( n = 6–10 mice per group). Data are shown as means ± SD from one of two independent experiments (D, F, H, and I). Statistical significance was determined using one-way ANOVA with Tukey’s multiple comparisons test (D). Log rank test was used (F, H, and I) for statistical comparison. n.s., not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The mouse colon cancer MC38 cell line (Cat. NO. NM-S13) and the pancreatic cancer KPC cell line (Cat. NO. NM-YD04) were purchased from Shanghai Model Organisms Center, Inc.

Techniques: Marker, Control, Flow Cytometry, Depletion Assay, Comparison

Journal: Cell Reports Medicine

Article Title: Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy

doi: 10.1016/j.xcrm.2026.102699

Figure Lengend Snippet: NOS2-high macrophages are significantly associated with Combo treatment efficacy (A) UMAP of macrophage subclusters from scRNA-seq data of MC38-bearing mice treated with control, MPLA+IFN-γ, αOX40, or Combo. Cells are color-coded by annotated subtype. (B) Bubble chart showing the top variable marker genes for identified macrophage subclusters. (C) Pie chart shows the relative abundance of four macrophage subclusters in control, αOX40, MPLA+IFN-γ, or Combo. (D) GO pathway analysis identifying significantly enriched signaling pathways in the Mac_S2 subcluster compared to other macrophage subpopulations. (E) Violin plots showing Nos2 expression levels across macrophage subclusters. (F) Violin plots comparing Nos2 and Cd206 expression levels among different treatment groups. (G) Frequency of M1-like, M2-like, or the ratio of M1/M2-like macrophage cells in tumor tissues from control, αOX40, MPLA+IFN-γ, and Combo groups with two time points, as determined by flow cytometry ( n = 5–10 mice per group). (H) Multiple immunofluorescence signal intensities of NOS2 + F4/80 + and CD206 + F4/80 + cells in the TME of control, αOX40, MPLA+IFN-γ, and Combo groups. Scale bars, 20 μm. Data are shown as means ± SD from one of two independent experiments (G and H). Statistical significance was determined using one-way ANOVA with Tukey’s multiple comparisons test (G). n.s., not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The mouse colon cancer MC38 cell line (Cat. NO. NM-S13) and the pancreatic cancer KPC cell line (Cat. NO. NM-YD04) were purchased from Shanghai Model Organisms Center, Inc.

Techniques: Control, Marker, Protein-Protein interactions, Expressing, Flow Cytometry, Immunofluorescence

Journal: Cell Reports Medicine

Article Title: Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy

doi: 10.1016/j.xcrm.2026.102699

Figure Lengend Snippet: NOS2-dependent direct tumor cell killing by macrophages in Combo therapy (A) Schematic of co-culture using CFSE-labeled MC38 cells with tumor- or spleen-derived macrophages, with/without NIL treatment. (B) Flow cytometry quantification of 7-AAD + MC38 cells after 48 h co-culture with tumor-(right) or spleen (left)-derived macrophages ( n = 3 biological replicates). (C) Quantification of 7-AAD + MC38 cells after 48 h in vitro co-culture with or without NIL treatment ( n = 3 biological replicates). (D) Treatment schedule for MC38- or B16-tumor-bearing Nos2 KOor WT mice treated with Combo ( n = 6 mice per group). (E and F) Survival curves of MC38-bearing (E) and B16-bearing mice (F) were analyzed using the log rank test. (G) Flow cytometry analysis of 7-AAD + MC38 cells after 48-h co-culture with CFSE-labeled MC38 cells and BMDMs from Nos2 KO mice ( n = 5 biological replicates). (H) Phagocytosis rate of MC38 cells engulfed by BMDMs was assessed by flow cytometry ( n = 3 biological replicates). (I) Surface expression of CRT on MC38 cells was assessed by flow cytometry after co-culture with MPLA- and IFN-γ-polarized BMDMs in vitro ( n = 3 biological replicates). (J) Analysis of CALR + MC38 cells from MC38-tumor-bearing mice following final treatment with control or Combo, assessed by flow cytometry ( n = 5 biological replicates). Data are shown as means ± SD from one of two independent experiments (B, C, E, F, G, H, I, and J). Statistical significance was determined using one-way ANOVA with Tukey’s multiple comparisons (B, C, and I) or using unpaired Student’s t test (G, H, and J). Log rank tests (E and F) were also used for statistical analysis. n.s., not significant; ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Combo, MPLA, and IFN-γ combined with αOX86 (E and F).

Article Snippet: The mouse colon cancer MC38 cell line (Cat. NO. NM-S13) and the pancreatic cancer KPC cell line (Cat. NO. NM-YD04) were purchased from Shanghai Model Organisms Center, Inc.

Techniques: Co-Culture Assay, Labeling, Derivative Assay, Flow Cytometry, In Vitro, Expressing, Control

Journal: Cell Reports Medicine

Article Title: Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy

doi: 10.1016/j.xcrm.2026.102699

Figure Lengend Snippet: Foxp3 + Treg depletion and macrophage reprogramming are involved in the anti-tumor effect of Combo (A) Flow cytometry analysis of TME. MC38-tumor-bearing mice were treated with control, αOX40, MPLA+IFN-γ, or Combo for two and three doses, and tumors were analyzed by flow cytometry. (B) Frequency and absolute count of CD25 + FOXP3 + cells in tumor tissues from control, αOX40, MPLA+IFN-γ, and Combo groups with two time points, as determined by flow cytometry ( n = 5 mice per group). (C) Treatment schedule for MC38-tumor-bearing Fcer1g KO or FcγRIIb KO mice. Mice were treated with Control, αOX40, MPLA+IFN-γ, and Combo every 3 days for a total of four doses. (D and E) Survival curves of Fcgr1g KO (D) and FcgrIIb KO (E) mice following treatment ( n = 5–6 mice per group) were monitored. (F) Treatment schedule. MC38-tumor-bearing mice were treated with MPLA and IFN-γ in combination with either OX40-mIgG2a or OX40-hIgG1 agonist antibodies (top), and the corresponding survival curves are shown (bottom) ( n = 5–7 mice per group). (G) Schematic of the co-culture experiment involving BMDMs and Tregs at a ratio of 1:4 (BMDM:Treg); Nos2 expression was measured by RT-qPCR. (H) Relative expression of Nos2 following the co-culture ( n = 4 biological replicates). (I) Multiple immunofluorescence (mIF) staining of MC38 tumors from mice treated with control, αOX40, MPLA+IFN-γ, or Combo, showing FOXP3 and NOS2 expression in border or intra-tumoral. Scale bars, 50 μm. (J) Analysis of cell numbers of FOXP3 and NOS2 expression at the border and intra-tumoral. Representative images from five randomly chosen fields were quantified with ImageJ. Data are shown as means ± SD from one of two independent experiments (B, D, E, F, H, and I). Statistical significance was determined using one-way ANOVA with Tukey’s multiple comparisons (B and H). Log rank test was also used (D–F). n.s., not significant; ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Combo, MPLA, and IFN-γ combined with αOX86 (C–E).

Article Snippet: The mouse colon cancer MC38 cell line (Cat. NO. NM-S13) and the pancreatic cancer KPC cell line (Cat. NO. NM-YD04) were purchased from Shanghai Model Organisms Center, Inc.

Techniques: Flow Cytometry, Control, Co-Culture Assay, Expressing, Quantitative RT-PCR, Immunofluorescence, Staining

Journal: Redox Biology

Article Title: PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy

doi: 10.1016/j.redox.2026.104075

Figure Lengend Snippet: Schematic illustration of the PD-L1-targeted photosensitizer chimera and its dual mechanism of action in cancer photoimmunotherapy. ( a ) Schematic structure of the PDTAC molecule. ( b ) Principle of singlet oxygen generated from photosensitizer. ( c ) Synergistic effects of PD-L1-drgradation and ICD-induction in cancer photoimmunotherapy.

Article Snippet: CT26, MC38 colon adenocarcinoma and CD274 Knockout cell line (MC38) cell lines were purchased from the Ubigene (Guangzhou, China).

Techniques: Generated

Journal: Redox Biology

Article Title: PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy

doi: 10.1016/j.redox.2026.104075

Figure Lengend Snippet: Synthesis and characterization of the PDTAC molecules. ( a ) Synthesis of PDTACs by SPPS. ( b ) Summary of the binding affinities toward PD-L1 measured by SPS. ( c ) Measurements of the binding affinity of PPA-VPF, PPA and VPF toward PD-L1 using SPR. ( d ) UV-Vis absorption spectra of PPA-VPF and VPF and in PBS or PBS/ACN (1:1). ( e ) Fluorescence spectra of PPA-VPF and VPF in PBS or PBS/ACN (1:1). ( f ). Amount of singlet oxygen generated from VPF and PPA-VPF (20 μM) in PBS or PBS/ACN (1:1) measured by EPR using 4-hydroxy-2,2,6,6-tetramethylpiperidine (4-OH-TEMP, 200 mM) as the spin trap. Light irradiation was performed using a 300 W Xenon arc lamp with a 600 nm bandpass filter (∼1.5 mW/cm 2 ) for the designated time.

Article Snippet: CT26, MC38 colon adenocarcinoma and CD274 Knockout cell line (MC38) cell lines were purchased from the Ubigene (Guangzhou, China).

Techniques: Binding Assay, Fluorescence, Generated, Irradiation

Journal: Redox Biology

Article Title: PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy

doi: 10.1016/j.redox.2026.104075

Figure Lengend Snippet: Targeting of PPA-VPF to PD-L1 in cancer cells. (a) Distribution of PPA-VPF or VPF in MC38 WT and PD-L1 KO cells revealed by confocal microscopy. Western blotting confirms PD-L1 knockout efficiency with β-actin as a loading control. (b) PD-L1 expression (green) and distribution of PPA-VPA or VPF (red) in MDA-MB-231 cells and MCF-7 cells at a concentration of 1 μM (incubated for 8 h). (c) Cellular adhesion of PPA-VPF and VPF in two breast cancer cell lines. (d) Time dependence of the cellular uptake of PPA-VPF and VPF in MDA-MB-231 cells. Scale bars represent 20 μm.

Article Snippet: CT26, MC38 colon adenocarcinoma and CD274 Knockout cell line (MC38) cell lines were purchased from the Ubigene (Guangzhou, China).

Techniques: Confocal Microscopy, Western Blot, Knock-Out, Control, Expressing, Concentration Assay, Incubation

Journal: Redox Biology

Article Title: PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy

doi: 10.1016/j.redox.2026.104075

Figure Lengend Snippet: In vitro photodegradation of PD-L1 in cancer cells. Analysis of PD-L1 abundance by western blotting ( a ), flow cytometry ( b, c ) and confocal imaging ( d ) in MDA-MB-231 cells. ( e ) Time dependence of PD-L1 degradation after PPA-VPF treatment and the blocking effect of chloroquine. ( f ) Coomassie blue staining of PD-L1 photolyzed in mixed solution (concentrations of PPA, PPA-VPF and VPF were 10 μM). ( g ) Time dependence of cellular PD-L1 distribution (green) after incubation with PPA-VPF (red). ( h ) Two mechanisms by which PPA-VPF degrades PD-L1 in cells. Irradiation was performed using a 300 W Xenon arc lamp (600 nm bandpass filter, 1.5 mW/cm 2 ) for the designated time. Scale bars represent 20 μm.

Article Snippet: CT26, MC38 colon adenocarcinoma and CD274 Knockout cell line (MC38) cell lines were purchased from the Ubigene (Guangzhou, China).

Techniques: In Vitro, Western Blot, Flow Cytometry, Imaging, Blocking Assay, Staining, Incubation, Irradiation

Journal: Redox Biology

Article Title: PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy

doi: 10.1016/j.redox.2026.104075

Figure Lengend Snippet: PPA-VPF resulting in immunogenic cell death in cancer cells. ( a ) Dose-dependent cytotoxicity of PPA-VPF under irradiation (5 min twice) in MC38 and PD-L1-KO-MC38 cells, and ( b ) in MDA-MB-231 (PD-L1 high) and MCF-7 (PD-L1 low) cells. ( c ) Dose-dependent cytotoxicity of PPA-VPF or VPF under irradiation (5 min twice) in normal 293T cells. HMGB1 release ( d ) and ATP release ( e ) from 4T1, MCF-7 and MDA-MB-231 cells photo-irradiated with VPF or PPA-VPF. ( f - g) Maturation of BMDCs cocultured with dying 4T1 cells photoirradiated with VPF or PPA-VPF. Irradiation was performed using a 300 W Xenon arc lamp (600 nm bandpass filter, 1.5 mW/cm 2 ) for the designated time. PPV was tested for comparison, and LPS (100 ng/mL) was used as a positive control.

Article Snippet: CT26, MC38 colon adenocarcinoma and CD274 Knockout cell line (MC38) cell lines were purchased from the Ubigene (Guangzhou, China).

Techniques: Irradiation, Comparison, Positive Control

Journal: Redox Biology

Article Title: PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy

doi: 10.1016/j.redox.2026.104075

Figure Lengend Snippet: Antitumor activity of PPA-VPF in mice engrafted with bilateral 4T1 tumors. ( a ) Procedures of tumor treatment. Growth curves, tumor growth inhibition rate and images of dissected xenografts of primary tumors ( b ) and distant tumodrs ( c ) with the indicated treatment in Balb/c mice xenografted with 4T1. ( d ) H&E staining and TUNEL analysis of the primary tumors after the indicated treatment. ( e ) Growth curve of 4T1 tumors in Balb/c nude mice with the indicated treatment. ( f ) Frequency of CD8 + CD3 + T cells in tumor-infiltrating lymphocytes and frequency of IFN-γ + CD8 + effector T cells in total CD8 + T cells collected from mice tumors after the indicated treatment . Quantification of relative PD-L1 content based on western blotting ( g ) and immunofluorescent staining of PD-L1 ( h ) in the primary tumors at the endpoint of the indicated treatment.

Article Snippet: CT26, MC38 colon adenocarcinoma and CD274 Knockout cell line (MC38) cell lines were purchased from the Ubigene (Guangzhou, China).

Techniques: Activity Assay, Inhibition, Staining, TUNEL Assay, Western Blot

Journal: Redox Biology

Article Title: PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy

doi: 10.1016/j.redox.2026.104075

Figure Lengend Snippet: Therapeutic response in MC38 and CT26 xenograft models. ( a ) Tumor growth curves from C57BL/6J mice (n = 4) with primary tumor samples. Treatment groups: vehicle control (PBS), PD-L1 KO, PPA-VPF (8 mg/kg), and PD-L1 KO with PPA-VPF. Light irradiation was performed using a 689 nm laser 24 h (PPA-VPF) or 30 min (VPF) after injection (100 mW/cm 2 for 8 min). ( b ) The xenografts obtained at the endpoint of the indicated treatments. ( c ) Tumor growth curves with representative primary tumor specimens from BALB/c mice (n = 4). ( d ) The images of dissected xenografts of primary tumors and distant tumors with the indicated treatment. Treatment groups: vehicle control (PBS), monotherapy PD-L1 antibody (5 mg/kg every three days over a 12-day course), monotherapy PPA-VPF (8 mg/kg every two days, administered thrice), combination therapy (PPA-VPF + PD-L1 antibody). Data represent mean ± SD. ( e ) IHC staining and analysis of CD3 expression in CT26 primary tumor following treatment PPA-VPF and PD-L1 antibody. Scale bar represents 10 μm.

Article Snippet: CT26, MC38 colon adenocarcinoma and CD274 Knockout cell line (MC38) cell lines were purchased from the Ubigene (Guangzhou, China).

Techniques: Clinical Proteomics, Control, Irradiation, Injection, Immunohistochemistry, Expressing